Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


S&N sells wound care products

This article was originally published in The Gray Sheet

Executive Summary

Advanced BioHealing acquires Smith & Nephew's Dermagraft tissue-engineered dermal replacement product for full-thickness diabetic foot ulcers and TransCyte temporary wound cover for serious burns. The May 31 product purchase, for undisclosed terms, dovetails with the start-up firm's R&D efforts in tissue engineering; the firm has a pending IDE for a keratinocyte-based bioengineered wound covering that does not require deep frozen storage. S&N indicated its interest in divesting the products in October 2005 to boost its "growth profile" after receiving an FDA "non-approvable" letter for an expanded Dermagraft indication to treat venous leg ulcers...

You may also be interested in...

Financings In Brief

Device VC activity increases

Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy

Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.

Pipeline Watch - ADD Meeting Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts